Gonadorelin

Most Common Uses

Gonadorelin is primarily used in medical settings to address reproductive and hormonal disorders. Physicians employ it to diagnose hypothalamic-pituitary-gonadal axis dysfunction, particularly in cases of delayed puberty or infertility, by assessing the pituitary gland’s response to stimulation. The peptide is also administered to induce ovulation in women with anovulatory infertility, supporting fertility treatments in assisted reproductive technologies. In men, Gonadorelin is used to treat hypogonadotropic hypogonadism, stimulating testosterone production and spermatogenesis.

Veterinarians utilize Gonadorelin in animal husbandry to manage reproductive cycles in livestock, such as inducing estrus in cows. Typically administered via intravenous or subcutaneous injection, dosing regimens are tailored to specific medical needs, often as a single dose for diagnostic purposes or in pulsed doses for therapeutic applications. Its use is limited to clinical settings under medical supervision due to regulatory oversight and the need for precise administration.

Mechanism of Action

Gonadorelin mainly works on the front part of the pituitary gland to control reproductive hormones. It attaches to GnRH receptors on special pituitary cells, causing them to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones then act on the gonads, boosting testosterone and sperm production in men, and estrogen production and ovulation in women.

The peptide is normally released in pulses, which imitates the body’s natural rhythm and ensures normal hormone levels. If given continuously, however, it can make the receptors less responsive, reducing hormone release in some treatments. Gonadorelin has a short lifespan in the body, about 10–40 minutes, which allows doctors to control its effects precisely. Its ability to cross into the brain and act directly on the pituitary makes it useful for treating infertility and other hormone-related issues.

Structure and Pharmacology

Gonadorelin is a synthetic decapeptide with the amino acid sequence H-Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (one-letter code: pEHWSYGLRPG-NH2). Its molecular formula is C55H75N17O13, and it has a molecular weight of 1182.3 g/mol. Identical to the naturally occurring gonadotropin-releasing hormone (GnRH), Gonadorelin features a pyroglutamyl residue at the N-terminus and an amidated C-terminus, which enhance its stability and receptor-binding affinity. This compact structure allows effective interaction with GnRH receptors in the pituitary gland, supporting its role in regulating reproductive hormone production.

Pharmacologically, Gonadorelin exerts its effects by binding to GnRH receptors on pituitary gonadotroph cells, stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones drive gonadal function, promoting testosterone production and spermatogenesis in males and estrogen production and ovulation in females. Pulsatile administration mimics the body’s natural GnRH secretion, ensuring physiological hormone release, while continuous dosing may desensitize receptors, suppressing hormone production for specific therapeutic purposes.

With a half-life of approximately 10–40 minutes, Gonadorelin requires frequent or carefully timed administration, typically via intravenous or subcutaneous injection, to achieve desired effects. Its ability to cross the blood-brain barrier enables direct interaction with pituitary tissues, making it effective for diagnostic testing of hypothalamic-pituitary-gonadal axis function and therapeutic applications in infertility and hypogonadism.

Dosages

Gonadorelin is administered primarily through intravenous or subcutaneous injection for diagnostic and therapeutic purposes in reproductive medicine. For diagnostic testing of hypothalamic-pituitary-gonadal axis function, a single dose of 100 micrograms (mcg) is typically given intravenously, with hormone levels measured afterward to assess pituitary response. In therapeutic settings, such as treating infertility or hypogonadotropic hypogonadism, Gonadorelin is often delivered via pulsatile infusion using a pump, with doses ranging from 5 to 20 mcg per pulse, administered every 90 to 120 minutes to mimic natural GnRH secretion.

For ovulation induction in women, treatment may continue for 7 to 14 days, adjusted based on clinical response. In men, similar pulsatile regimens support testosterone production and spermatogenesis over weeks to months. Subcutaneous injections, when used, typically involve 100 to 200 mcg daily, divided into multiple doses. Dosing schedules are tailored to the patient’s needs to optimize outcomes.

Warnings and Cautions

Gonadorelin requires careful administration to ensure safety in clinical settings. Patients with known hypersensitivity to Gonadorelin or its components should avoid its use, as allergic reactions, such as rash, swelling, or anaphylaxis, may occur and necessitate immediate medical attention. Those with hormone-dependent conditions, such as prostate or breast cancer, need close monitoring, as Gonadorelin’s stimulation of luteinizing hormone and follicle-stimulating hormone may exacerbate these conditions. Women receiving Gonadorelin for ovulation induction face a risk of ovarian hyperstimulation syndrome, which can cause abdominal pain, bloating, or fluid retention, requiring prompt medical evaluation.

Pregnant women should not use Gonadorelin, as its effects on fetal development are not fully studied. Common side effects include injection site reactions, headache, or nausea, and persistent symptoms warrant medical review. Prolonged use may lead to pituitary desensitization, reducing treatment efficacy. Proper monitoring and adjustment of therapy is required to minimize risks and optimize outcomes.

Research & Clinical Trials

Gonadorelin Induces Ovulation in Oestrous Queens

This study found that giving female cats (queens) a single injection of 50 µg of gonadorelin into the muscle can effectively trigger ovulation during their heat period. Two days after the injection, all the treated cats stopped showing signs of being in heat, like restlessness or calling. When the researchers examined the ovaries a few days later, they found that 84% of the treated cats had successfully ovulated and developed multiple corpora lutea, which are the structures formed after ovulation. In contrast, only 37% of the cats that received a placebo (just a saline injection) ovulated. This study is significant because it is the first to show that this specific dose of gonadorelin, given on days 2 to 4 of the cat’s heat cycle, can reliably cause ovulation, making it potentially useful for managing breeding or reproductive health in cats. [1]

Gonadorelin Pump vs. Gonadotropin for CHH Spermatogenesis

The study found that in men with congenital hypogonadotropic hypogonadism (CHH), using a pulsatile gonadorelin pump (PGP) helped start sperm production faster than cyclical gonadotropin therapy (CGT). Men on PGP began producing sperm after about 6 months on average, while those on CGT took around 14 months. Overall, 90% of men using PGP and 83.3% of men using CGT successfully produced sperm, though the small number of participants made it hard to say for sure which method was better.

Factors that made sperm production more likely included having had hormone treatments before and having a stronger initial response of luteinizing hormone (LH). Both treatments led to larger testicles and longer penises. However, CGT often caused higher and more uneven testosterone levels, which sometimes led to side effects like acne and breast tenderness, while PGP more commonly caused mild skin reactions at the needle site. [2]